Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
acute treatment
maintenance treatment |
| gptkbp:contraindication |
severe liver impairment
concurrent use of certain medications hypersensitivity to aripiprazole |
| gptkbp:dosage_form |
long-acting injectable
|
| gptkbp:effective_date |
2015-09-01
|
| gptkbp:form |
injectable suspension
|
| gptkbp:frequency |
once a month
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sustenna
|
| gptkbp:ingredients |
gptkb:aripiprazole
|
| gptkbp:label |
black box warning
monitoring for metabolic changes monitoring for movement disorders patient counseling information risk of suicidality |
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
dopamine D2 receptor partial agonist
serotonin 5-HT2 A receptor antagonist serotonin 5-HT1 A receptor agonist |
| gptkbp:packaging |
single-dose vial
|
| gptkbp:patient_population |
adults
adolescents |
| gptkbp:pharmacokinetics |
long half-life
steady-state concentration achieved after 3 months |
| gptkbp:provides_guidance_on |
gptkb:National_Institute_for_Health_and_Care_Excellence
gptkb:American_Psychiatric_Association |
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:side_effect |
anxiety
nausea restlessness drowsiness insomnia cardiovascular events weight gain hyperglycemia extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia |
| gptkbp:storage |
room temperature
|
| gptkbp:trade |
gptkb:Abilify_Maintena
|
| gptkbp:used_for |
schizophrenia
bipolar disorder |
| gptkbp:bfsParent |
gptkb:Invega_Sustenna
|
| gptkbp:bfsLayer |
7
|